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Introduction: As even small concentrations of acetate in the plasma result in pro-inflammatory and cardiotoxic
effects, it has been removed from renal replacement fluids. However, Plasma-Lyte 148 (Plasma-Lyte), an electrolyte
replacement solution containing acetate plus gluconate is a common circuit prime for cardio-pulmonary bypass
(CPB). No published data exist on the peak plasma acetate and gluconate concentrations resulting from the use of
Plasma-Lyte 148 during CPB.
Methods: Thirty adult patients were systematically allocated 1:1 to CPB prime with either bicarbonate-balanced
fluid (24 mmol/L bicarbonate) or Plasma-Lyte 148. Arterial blood acetate, gluconate and interleukin-6 (IL-6) levels
were measured immediately before CPB (T1), three minutes after CPB commencement (T2), immediately before
CPB separation (T3), and four hours post separation (T4).
Results: Acetate concentrations (normal 0.04 to 0.07 mmol/L) became markedly elevated at T2, where the Plasma-
Lyte group (median 3.69, range (2.46 to 8.55)) exceeded the bicarbonate group (0.16 (0.02 to 3.49), P < 0.0005). At
T3, levels had declined but the differential pattern remained apparent (Plasma-Lyte 0.35 (0.00 to 1.84) versus
bicarbonate 0.17 (0.00 to 0.81)). Normal circulating acetate concentrations were not restored until T4. Similar
gluconate concentration profiles and inter-group differences were seen, with a slower T3 decay. IL-6 increased
across CPB, peaking at T4, with no clear difference between groups.
Conclusions: Use of acetate containing prime solutions result in supraphysiological plasma concentrations of
acetate. The use of acetate-free prime fluid in CPB significantly reduced but did not eliminate large acetate surges
in cardiac surgical patients. Complete elimination of acetate surges would require the use of acetate free bolus
fluids and cardioplegia solutions.
Trial registration: Australia and New Zealand Clinical Trials Register (ANZCTR): ACTRN12610000267055
Introduction
Open heart surgery utilizing cardio-pulmonary bypass
(CPB) is the most common method of cardiac surgery
worldwide [1]. A potential complication [2] of CPB is
metabolic acidosis, which is influenced by the CPB cir-
cuit priming fluid [3,4]. Attempts to prevent metabolic
acidosis have entailed alterations to circuit prime fluids,
including partial replacement of chloride by rapidly
metabolised anions such as L-lactate [5,6], acetate and
g l u c o n a t e[ 3 , 7 ] ,o re l s eb yb i c a r b o n a t e[ 8 ] .P l a s m a - L y t e
148 (Baxter, Toongabbie, NSW, Australia) is a crystal-
loid CPB prime fluid in common use in Australia and
New Zealand (personal communication, Andrew McLa-
ren, Baxter, Australia) in about 7% of surveyed units in
the UK [9] and in some units in North America [10].
One litre of Plasma-Lyte 148 contains 27 mmol acetate
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any medium, provided the original work is properly citedand 23 mmol gluconate. In a recent Phase II evaluation
of Plasma-Lyte 148 versus a bicarbonate balanced
prime, CPB commencing with Plasma-Lyte 148 prime
was associated with an immediate surge in unmeasured
anions of >10 mEq/L, with residual elevations still pre-
sent just prior to CPB cessation [8]. Liskaser and collea-
gues have reported a similar phenomenon [3]. In both
studies the unmeasured anions were considered to be
acetate and gluconate; however, neither study measured
individual concentrations of either anion at any time
point.
Acetate surges in the vasculature may not be benign.
For example, in renal replacement therapy, the pro-
inflammatory, vasodilatory, myocardial depressant and
hypoxaemia promoting properties of acetate [11-17] led
to its removal from contemporary renal replacement
fluids. Nevertheless, acetate remains an integral compo-
nent of commonly used CPB pump prime solutions. Lit-
tle is known of the acetate concentration profile and
consequent physiological impact during cardiac surgery
incorporating exposure to acetate-based fluid. The situa-
tion concerning gluconate is equally unclear, despite its
widespread use.
In this context, we measured concentrations of acetate
and gluconate before, during and after CPB primed with
either Plasma-Lyte 148 or an alternative bicarbonate-
balanced crystalloid preparation. We also collected
p r e l i m i n a r yd a t ao np l a s m aI L - 6c o n c e n t r a t i o n sa sa
marker of the systemic inflammatory response accompa-
nying CPB.
Materials and methods
The protocol was approved by the Human Research Ethics
Committee of the Princess Alexandra Hospital and written
informed consent was obtained from the patients prior to
enrolment (Australian New Zealand Clinical Trials Regis-
try number ACTRN12610000267055).
Patients scheduled for elective cardiac surgery were
eligible for enrolment. Exclusion criteria were an abnor-
mal pre-operative venous plasma bicarbonate concentra-
tion (<22 mmol/L or >27 mmol/L), hypercapneic
respiratory failure, an elevated plasma creatinine con-
centration (>120 micromol/L), diabetes mellitus or
chronic liver disease.
Patients were assigned systematically to Plasma-Lyte
148 or bicarbonate fluid according to the identity of the
available whole-body perfusionist. In the absence
of investigator PGD as perfusionist, patients received car-
diopulmonary circuit prime as normal with 2 L of
Plasma-Lyte 148. In the presence of investigator PD as
perfusionist the CPB circuit was primed with 2 L of
bicarbonate-balanced fluid made up in the pump imme-
diately prior to priming the circuit by sequential addition
of 0.9% saline 1,130 mL, 0.45% saline 822 mL (Baxter
Healthcare, Toongabbie, NSW, Australia) and 8.4% sodium
bicarbonate 48 mL (Astra Pharmaceuticals, Sydney, NSW,
Australia). The electrolyte compositions of bicarbonate-
balanced fluid and Plasma-Lyte 148, along with the
cardioplegia solution employed, are set out in Table 1.
The CPB circuit incorporated a membrane oxygenator
(Dideco Avante, Cellplex, Sorin, Mirondola, Italy) and
heart lung machine (Jostra HL 20, Maquet Critical Care
A B ,S o l n a ,S w e d e n ) .T h es t a n d a r dp u m pr a t ew a s2 . 4L /
minute/m
2 and the target temperature ranged from 32°C
to 35°C. Arterial blood was sampled at four time points:
T1, immediately before commencing CPB; T2, two
minutes after commencement of CPB, prior to place-
ment of the aortic cross-clamp; T3, on rewarming, just
prior to separation from CPB; T4, four hours after
separation from CPB.
Measurements at each time point included plasma
acetate, gluconate and IL-6 concentrations. Acid-base
data were also collected, and are the subject of a sepa-
rate report. No fluids apart from the patient’s allocated
prime (Plasma-Lyte 148 or bicarbonate-balanced) were
infused in the interval between T1 and T2. Between T2
and T3, cardioplegia was administered. In accord with
standard clinical practice at the research centre, an addi-
tional Plasma-Lyte 148 boluses were administered to any
patient regardless of experimental group if volume sup-
plementation was required.
Acetate and gluconate assay
Plasma acetate and gluconate concentrations were mea-
sured by commercially available kits (Megazyme, Minto,
NSW, Australia). Acetate determination is based on the
formation of NADH which is measured by the increase in
absorbance at 340 nm. Gluconate determination is based
on the amount of NADPH formed in the reaction which is
stoichiometric with the amount of D-gluconic acid and
measured by the increase in absorbance at 340 nm.
IL-6 assay
Plasma IL-6 was measured using an ELISA technique
(Jomar Bioscience Ltd, Kensington, SA). The detection
Table 1 Composition of cardiopulmonary bypass circuit
priming fluids and cardioplegia solution
Plasma-Lyte 148 Bicarbonate-balanced Cardioplegia
Na
+ 140 140 140
Cl
- 98 116 256
K







All concentrations in mmol/L.
Davies et al. Critical Care 2011, 15:R21
http://ccforum.com/content/15/1/R21
Page 2 of 8antibody was a biotin conjugate antihuman IL-6.
Recombinant human IL-6 was used as a standard.
The laboratory scientists performing the acetate, glu-
conate and the IL-6 assays were blinded to the group
allocation.
Data analysis
Initial exploratory data analysis involved calculation of
summary statistics (non-parametric (Wilcoxon), (t-test)
and Fisher exact tests as appropriate) and construction
of trajectory plots according to treatment group. Follow-
ing inspection of these plots, group differences for the
change from baseline at selected time points in continu-
ous outcome variables were compared after adjustment
for baseline (T1) values using a simple analysis of covar-
iance (ANCOVA) regression model. Natural logarithmic
transformations were applied to stabilize the variance of
circulating acetate, gluconate and IL-6 levels.
Finally, a population-averaged generalized linear
model using a generalized estimating equation (GEE)
approach with an unstructured working correlation
matrix and robust standard error estimates adjusted for
clustering within individual subjects was applied to
these longitudinal data to evaluate the overall associa-
tions of the vector of (log transformed) acetate, gluco-
nate and IL-6 levels with treatment group across the
four time points. Multiple imputation for missing log
acetate data was used to support conclusions from the
standard generalized linear model.
Statistical analyses were performed using SAS version
9.1 for Windows (SAS Institute, Carey, NC, USA) and
Stata version 11.1 (StataCorp. 2010. Stata Statistical
Software: Release 11.1. College Station, TX, USA: Stata-
Corp LP).
Results
The patients’ demographic details, type of surgery, CPB
and post-CPB data are summarized in Table 2 according
to trial fluid treatment. The Plasma-Lyte 148 and bicar-
bonate-balanced treatment groups were similar with
respect to age and sex, operative type, CPB times, clamp
times, volumes of administered cardioplegia, Euro-
SCORE and Parsonnet indices, incidence of new post-
operative atrial fibrillation and frequency of inotrope
use. All patients were discharged from the cardiac post-
operative unit within 24 hours, and all survived to hos-
pital discharge.
Plasma acetate and gluconate and IL-6
Arterial blood acetate and gluconate and IL-6 levels,
according to time of sample collection, are summarized
in Table 3. As well, the time course of each individual
subject’s acetate and gluconate and IL-6 is illustrated
respectively in Figures 1, 2 and 3
Acetate
Baseline (T1) arterial acetate concentrations were ele-
vated above the normal range (0.04 to 0.07 mmol/L) in
both groups [18]. These circulating acetate levels
became markedly elevated at T2, where, accounting for
the (log) acetate levels at baseline, there was very strong
evidence (P < 0.0005) of a differential elevation of
acetate at T2 compared to T1 in those allocated to
Plasma-Lyte 148 compared to bicarbonate fluid. By T3,
the substantially higher acetate concentrations in the
Plasma-Lyte 148 group were diminished, but relatively
normal concentrations were not restored in either group
until T4 (Figure 1 and Table 3).
Gluconate
Overall gluconate levels were also greatest at T2 (Figure
2 and Table 3). Accounting for (log) gluconate levels at
baseline, there was also very strong evidence (P <
0.0005) of a differentially elevated gluconate level at T2
compared to T1 for patients receiving Plasma-Lyte 148
relative to bicarbonate-balanced fluid. Subsequent circu-
lating gluconate levels declined more slowly than for
acetate in patients receiving Plasma-Lyte 148, to again
approximate baseline values by T4 in both groups.
Interleukin-6
In contrast to acetate and gluconate, overall IL-6 levels
increased progressively over time, reaching their maxi-
mum values at T4 (Figure 3 and Table 3). Although IL-
6 levels were higher at T2 in the Plasma-Lyte group
(P < 0.05), accounting for the (log) IL-6 levels at base-
line, there was no strong evidence (P = 0.12) of a differ-
ence between the two groups in the change in
circulating (log) IL-6 levels from T1 to T4.
Overall population-averaged model
A marginal population-averaged linear regression model
using the GEE approach also returned very strong evi-
dence (P < 0.0005) of an independent differential asso-
ciation between administration of Plasma-Lyte 148
versus bicarbonate-balanced fluid as CPB prime fluid
and elevated (log) circulating acetate levels across time,
specifically at T2.
Discussion
To our knowledge, this is the first report of serial
plasma acetate and gluconate concentrations during and
after CBP using Plasma-Lyte 148 prime. We found
supra-physiological surges of both anions soon after
institution of CBP with Plasma-Lyte 148, with persistent
elevations at the end of bypass, particularly of gluconate.
This study documents previously suspected but
incompletely characterized effects on serial plasma acet-
ate and gluconate concentrations during and after CPB
using Plasma-Lyte 148 as a CPB circuit priming fluid. It
is noteworthy that in both groups, pre-bypass acetate
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viously reported normal human concentrations of 0.04
to 0.07 mmol/L [19]. Although increases of both anions
were also observed in the group allocated to bicarbo-
nate-balanced CPB prime fluid, these surges were smal-
ler than with Plasma-Lyte 148. There are a number of
potential explanations for these findings. First, several
patients in both groups were likely to have received
Plasma-Lyte 148 before the institution of CPB, as
Plasma-Lyte 148 was at the clinical research site the
default supplementary fluid for volume loading in either
group. It is common practice at the Princess Alexandra
Hospital to infuse approximately 1L of crystalloid at
induction of anaesthesia. Second, all patients received
on average over 300 mL of cardioplegia solution in early
CPB prior to T3, with this solution containing acetate
and gluconate in concentrations similar to Plasma-Lyte
148 (Table 1). Finally, elevated blood acetate concentra-
tions have been reported in patients with type 2 diabetes
mellitus [20]. Diabetes was an exclusion criterion for
this study, but sub-clinical disease may have been pre-
sent in some patients.
Although there are no comparative published human
reference ranges, it is likely the pre-bypass circulating
gluconate concentrations observed in this study were
also above normal, related to pre-bypass fluid loading
with Plasma-Lyte 148 in numerous patients. Gluconate
is known to be eliminated more slowly [21] than acetate.
T h el a t t e ru n d e r g o e sr a p i dm e t a b o l i s ma tar a t eo f3 0 0
mmol/h in health [22], with a significant extra-hepatic
component [13]. This rapid clearance of acetate is pre-
served in experimental shock states [23], which may in
part explain the choice of acetate in preference to
L-lactate in ‘balanced’ resuscitation fluids such as
Plasma-Lyte 148. Current data on gluconate metabolism
and toxicity in humans are limited, and it is unknown
to what extent CPB alters acetate or gluconate turnover.
Plasma IL-6 concentrations increased during and in
the early hours following CPB in both groups. The
greatest concentrations observed in this study were at
four hours following cessation of CPB, consistent with
previously reported maxima at three to six hours post
CPB [24,25]. Unlike acetate and gluconate, IL-6 levels
did not show strong evidence of differential changes
over time between treatment groups, but the small size
of the study precludes assessment of potentially subtle
changes.
It remains unresolved whether the demonstrated
supra-physiological concentrations of either anion could
cause harm. The answer cannot be found in this small
non-randomised, incompletely matched cohort study,
particularly since substitution of bicarbonate in the
circuit prime failed to eliminate exposure to supra-
physiological concentrations of acetate and gluconate,
for reasons already discussed. However, there is already
unequivocal evidence of acetate toxicity in contexts
other than CPB. A number of studies have documented
hypoxia and hypotension when patients with end stage
renal disease were dialysed against solutions containing
acetate [12,13,15]. There is also evidence of cytokine
release, carbohydrate intolerance, disturbances of fatty
acid synthesis, reduction of cytosolic redox potential,
intracellular accumulation of phosphate, pyrophos-
phate, phosphorylated intermediates and calcium, and
Table 2 Patient characteristics according to study fluid
Bicarbonate-balanced Plasma-Lyte 148
N =1 5 N P =1 5 P
Age, mean (SD), y 68 (8) 68 (9) 1.0*
Sex, male 12 11 1.0
†
Surgical type
CABG 11 12 0.7
†
Valve 4 3 1.0
†
CPB time, mean (SD), min 81 (31) 80 (20) 0.93*
Clamp time, mean (SD), min 54 (29) 58 (20) 0.69*
Cardioplegia volume, mean (SD), mL 325 (137) 340 (121) 0.74*
Euro score, median [range] 3 (0 to 10) 3 (1 to 7) 0.9
‡
Parsonnet score, median [range] 8 (3 to 22) 8 (3 to 26) 0.54
‡
New onset atrial fibrillation, n 4 3 1.0
†
Inotrope use, n 2 4 0.65
†
ICU survival, n 15 15 1.0
†
Hospital survival, n 15 15 1.0
†
* T test.
† Fisher exact test.
‡ Wilcoxon rank sum test.
CABG, coronary artery bypass grafting.
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sium pyrophosphate [13].
Acetate has also been implicated in direct myocardial
toxicity. Patients with chronic renal failure receiving
acetate-free haemodiafiltration achieved better stroke
volumes, demonstrated a lesser reduction in peripheral
resistance and recorded smaller troponin increases
than patients receiving conventional acetate-based
dialysis [17]. In an isolated perfused rat heart model,
exposure of myocardial tissue to acetate concentrations
as low as 5 mmol/L resulted in impaired fatty acid oxi-
dation and decreased ATP turnover [16]. Finally,
Plasma-Lyte 148, although promoted as a resuscitation
solution, performed poorly in a haemorrhagic shock
model. Traverso et al. compared four resuscitation
crystalloids [26], and found that Plasma-Lyte148 was
associated with a lower survival and a late rise in plasma
L-lactate concentrations as compared with normal saline
and Ringer’s lactate solutions.
Acetate-based haemodialysis in Australia and else-
where has been abandoned, even in supplementary con-
centrations although it continues to be an integral
component of ‘balanced’ resuscitation fluids, CPB prim-
ing solutions and total parenteral nutrition. During CPB,
adverse effects triggered by acetate exposure would be
d i f f i c u l tt od e t e c ta m o n g s tthe vigorous metabolic and
host defence responses to surgery [18,27], hypothermia,
and non-pulsatile blood flow [1]. Although there is no
proven detrimental effect, the concentrations documen-
ted in this report suggest a need for further investiga-
tions into the safety of acetate containing fluids during
CPB. Even more importantly, these investigations should
also address the practice of infusing high concentrations
of acetate directly into the coronary circulation as part
of cardioplegia solution.
Surges in circulating gluconate levels observed in this
study were also marked, especially in the Plasma-Lyte
148 group. Unlike acetate, there is no current evidence
of clinical or experimental gluconate toxicity, although
information is limited. Animal data suggest that at con-
centrations of 2.4 and 4.8 mmol/L, gluconate may pro-
vide protection against post ischemic myocardial
dysfunction and oxidative injury [28]. Gluconate has
also been incorporated into some enteral and parenteral
pharmaceutical preparations. The principal benefit of
bicarbonate-balanced fluids demonstrated thus far, apart
from avoidance of exogenous anions, is the ability to
achieve a well balanced acid-base status across CPB [8].
Also, there is now evidence that added sodium bicarbo-
nate may exert a renal protective effect in CPB [29].
The main difficulty associated with the use of bicarbo-
nate is the need to prevent CO2 loss during preparation
and storage [30], and the tendency for precipitation on
exposure to small concentrations of calcium and
magnesium.
Conclusions
The use of Plasma-Lyte 148 as a prime fluid resulted in
supra-physiological concentrations of acetate and gluco-
nate across CPB. A bicarbonate-balanced pump prime
fluid substantially reduced but did not eliminate surges
of both anions, due to uncontrolled, clinically-directed
Table 3 Untransformed acetate, gluconate and
interleukin 6 levels according to time of collection
Variable Fluid T1 T2 T3 T4
Acetate (mmol/L) Bicarbonate mean 0.17 0.49 0.24 0.03
SD 0.17 0.94 0.23 0.03
min 0 0.02 0 0
median 0.13 0.16 0.17 0.03
max 0.64 3.49 0.81 0.08
P148 mean 0.21 4.29 0.49 0.03
SD 0.18 1.76 0.53 0.06
min 0 2.46 0 0
median 0.18 3.69 0.35 0
max 0.54 8.55 1.84 0.23
Gluconate (mmol/L) Bicarbonate mean 0.89 1.28 2.13 0.69
SD 0.54 1.50 1.05 0.38
min 0.05 0.32 0.88 0.30
median 0.93 0.75 2.10 0.60
max 1.70 6.13 3.95 1.82
P148 mean 1.20 7.44 4.31 1.33
SD 0.74 1.99 1.18 0.73
min 0.04 4.92 2.38 0.50
median 1.07 6.95 3.97 1.18
max 3.18 12.1 6.51 3.42
IL-6 (pg/mL) Bicarbonate mean 1.75 1.88 10.3 72.5
SD 0.81 0.92 13.4 49.7
min 0.51 0.74 1.67 12.1
median 1.69 1.55 7.14 47.9
max 3.76 3.68 57.2 180
P148 mean 5.99 4.72 19.2 119
SD 12.4 8.07 21.4 74.5
min 1.06 0.89 1.84 29.0
median 2.65 2.7 12.5 113
max 50.3 33.6 62.2 309
T1 Immediately before commencing CPB.
T2 Two minutes after commencement of CPB, prior to placement of the aortic
cross-clamp.
T3 On rewarming, just prior to separation.
T4 4 hours after separation from CPB.
SD, standard deviation; Min, minimum value; max, maximum value;
Bicarbonate, bicarbonate-balanced fluid; P148, Plasma-Lyte 148 fluid.
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Figure 2 Plasma gluconate trajectory plots according to CPB prime, with geometric mean at each time point.
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nate, especially cardioplegia solution. While no clear dif-
ferences in systemic inflammation were demonstrated,
as reflected by circulating IL-6 levels, larger scale studies
would be required for more precise assessment of this
possibility. Currently, the use of acetate-free prime fluid
in CPB cannot completely eliminate clinical exposure to
large acetate surges until acetate is also removed from
all other fluids used in CPB, including cardioplegia and
bolus fluids. The impact of large plasma concentrations
of gluconate also needs further elucidation.
Key messages
￿ As even small concentrations of acetate in the
plasma result in pro-inflammatory and cardiotoxic
effects, it has been removed from renal replacement
fluids.
￿ Acetate containing crystalloids are commonly used
as prime solutions in cardiopulmonary bypass.
￿ This study has identified that supraphysiological
concentrations of acetate and gluconate are reached
in the plasma of patients undergoing cardiopulmon-
ary bypass with Plasma-Lyte 148 as a prime solution.
￿ The use of acetate-free prime fluid in CPB signifi-
cantly reduced but did not eliminate large acetate
surges in cardiac surgical patients.
￿ Complete elimination of acetate surges would
require the use of acetate free bolus fluids and cardi-
oplegia solutions.
Abbreviations
CABG: coronary artery bypass grafts; Cl
-: chloride; CPB: cardiopulmonary




+: sodium; P148: plasmalyte 148.
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Figure 3 Plasma IL-6 trajectory plots according to CPB prime, with geometric mean at each time point.
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